Literature DB >> 1539845

A double-blinded comparison of metoclopramide and droperidol for prevention of emesis following strabismus surgery.

D M Lin1, S R Furst, A Rodarte.   

Abstract

Vomiting in the postoperative period is common in children after strabismus surgery. One hundred ten pediatric patients, ages 8 months to 14 yr, admitted for outpatient strabismus surgery were enrolled in a randomized, double-blinded study to compare droperidol and metoclopramide to placebo for the prevention of postoperative emesis. Each child was prospectively assigned at random to one of four treatment groups: metoclopramide 0.15 mg/kg, metoclopramide 0.25 mg/kg, droperidol 0.075 mg/kg, or saline control. Drugs were administered intravenously immediately after induction of inhalation anesthesia. No neuromuscular blocking agents were used. Tracheal extubation was performed while patients were still deeply anesthetized. Acetaminophen and meperidine were given in standard doses for postoperative pain to all children. The incidence of vomiting was less in both the droperidol (33%) and metoclopramide 0.25 mg/kg (29%) groups when compared to controls (88%) (P less than 0.01). Patients receiving metoclopramide 0.15 mg/kg had a 68% incidence of vomiting (P not significant). The mean frequency of emesis was reduced in all treatment groups compared with control (P less than 0.05). Patients receiving droperidol and metoclopramide 0.25 mg/kg also had decreased postoperative stays (metoclopramide 201 min; droperidol 213 min) versus control (258 min, P less than 0.05). No child exhibited extrapyramidal symptoms, excessive drowsiness, or agitation. We conclude that metoclopramide in a dose of 0.25 mg/kg, administered prior to the start of surgery, is at least as effective as droperidol in preventing postoperative emesis and can reduce the time to patient discharge compared to control.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1539845     DOI: 10.1097/00000542-199203000-00006

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  15 in total

Review 1.  Risks and benefits of drugs used in the management of postoperative nausea and vomiting.

Authors:  Y F Sung
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 2.  Recovery room problems or problems in the PACU.

Authors:  D K Rose
Journal:  Can J Anaesth       Date:  1996-05       Impact factor: 5.063

3.  Antiemetic efficacy of granisetron and metoclopramide in children undergoing ophthalmic or ENT surgery.

Authors:  Y Fujii; H Toyooka; H Tanaka
Journal:  Can J Anaesth       Date:  1996-11       Impact factor: 5.063

4.  Are antiemetics cost-effective for children?

Authors:  J Lerman
Journal:  Can J Anaesth       Date:  1995-04       Impact factor: 5.063

Review 5.  [Prophylaxis of nausea and vomiting in the postoperative phase: relative effectiveness of droperidol and metoclopramide].

Authors:  M Merker; P Kranke; A M Morin; D Rüsch; L H J Eberhart
Journal:  Anaesthesist       Date:  2010-12-12       Impact factor: 1.041

Review 6.  Intranasal metoclopramide.

Authors:  D Ormrod; K L Goa
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

7.  Granisetron reduces vomiting after strabismus surgery and tonsillectomy in children.

Authors:  Y Fujii; H Tanaka; H Toyooka
Journal:  Can J Anaesth       Date:  1996-01       Impact factor: 5.063

Review 8.  Management of postoperative nausea and vomiting in children.

Authors:  Pasquale De Negri; Giorgio Ivani
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 9.  Acute gastroenteritis in children: role of anti-emetic medication for gastroenteritis-related vomiting.

Authors:  Alexander K C Leung; Wm Lane M Robson
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 10.  The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis.

Authors:  Melissa Lau Moon Lin; Paula D Robinson; Jacqueline Flank; Lillian Sung; L Lee Dupuis
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.